Emerging helium and natural gas producer Renergen has designed and patented a solution for the efficient transport and storage of ultra-cold biologics for periods up to 25 days or longer in transit, where access to an external power source is not available.Known as Cryo-Vacc, it has a temperature range of -150 ̊C to 8 ̊C, making it highly versatile for a range of vaccines.The device is fitted with cold chain monitoring and asset tracking technology and can provide accurate temperature readings of vaccines whilst in transit, as well as GPS tracking to ensure the custody chain can be audited.According to a spokesman for Renergen, Cryo-Vacc is ideal for air and ground transportation, utilising liquid nitrogen to transport by road and helium to transport by air. Aside from the fact that helium is only a fraction of the weight of nitrogen, significantly reducing its cost in airfreight, when used in Cryo-Vacc helium can also accommodate up to 12 times more vials per f light compared to other cryogens based on current f light safety regulations.“Precise temperature control, combined with a formidable hold time in transit, makes Cryo-Vacc a compelling asset in the transport of biologics, especially in the developing world,” said Renergen CEO Stefano Marani in a statement.The company has teamed up with local express courier partner, DPD Laser.FN9037Tigers is a client interfacing development company specialising in bespoke supply chain solutions, customs brokerage, e-fulfilment, perishables and transportation by air, sea and road.www.go2tigers.com | za-info@go2tigers.com | 011 923 4200With most of the vaccines distributed in South Africa being imported, the need for large-scale cold chain storage has become very apparent.– Sean Petzer“